Abagovomab

Summary

Abagovomab (CHEMBL1742981) is a phase-3 clinical-stage antibody; indicated across 3 conditions including ovarian cancer and peritoneal neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 3 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1742981
Name	Abagovomab
Type	Antibody
Max phase	3

Also known as: Abagovomab, ACA-125, MEN-2234, ABAGOVOMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ovarian cancer	2	MONDO:0008170	MONDO:0008170
peritoneal neoplasm	1	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	1	MONDO:0021092	MONDO:0002158

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00418574	PHASE2/PHASE3	TERMINATED	Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
NCT00058435	PHASE1	COMPLETED	Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).